Grants for Public housing authorities - Federal

This funding opportunity supports research to develop and test behavioral sleep interventions for adolescents and young adults facing mental health challenges.

Substance use needs to be better incorporated into interventions for the engagement and retention of sexual minority persons in prevention and care with attention to emergent interventions such as long-acting PrEP. Social determinants of health associated with HIV and problematic substance use such as homelessness and criminal justice involvement also demonstrate disproportionate impact among sexual and gender minorities and need attention. Changing self-definition of sexual minority status has implications for outreach and provider stigma and needs to be better integrated into interventions. This initiative will address these gap areas and support epidemiologic, intervention, and implementation research that incorporates attention to HIV as a syndemic including comorbidities such as STIs, HCV, and psychiatric disorder.

This funding opportunity supports researchers in analyzing and integrating existing data to better understand cancer risks and outcomes, ultimately advancing cancer research and treatment strategies.

The National Cancer Institute intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications forresearch on the confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This NOFO will utilize the R01 grant mechanism (clinical trial optional). Up to six (6) R01 awards are expected to be funded as part of the initiative. Research projects search project will advance the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assess the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverage stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promote research in diverse domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 39 minutes. Presentation slides are downloadable at: https://deainfo.nci.nih.gov/advisory/joint/0624/Vanderpool.pdf.

This grant provides funding for a Data Coordinating Center to support research projects focused on preventing stillbirth, emphasizing collaboration and equity in addressing disparities in vulnerable populations.

The "Research on Autism Spectrum Disorders" grant aims to fund projects that explore the causes, prevalence, diagnosis, and best service delivery methods for Autism Spectrum Disorders, with a focus on small, well-defined projects that can be completed within two years using limited resources.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

This funding opportunity provides financial support to the American College of Radiology to establish a center that will enhance radiotherapy and imaging services for clinical trials in cancer research across the National Clinical Trials Network.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports small-scale brain imaging research related to substance use and addiction, aimed at helping both new and established researchers develop innovative studies that enhance our understanding of neurobiological mechanisms in these areas.

This funding opportunity supports research teams from various sectors to explore how sex differences influence the biological factors related to Alzheimer’s disease and its treatment, aiming to enhance understanding and improve precision medicine approaches.

This funding opportunity supports collaborative research projects aimed at understanding and treating infectious and immune-related diseases, open to a wide range of organizations including universities, nonprofits, and government entities.

This grant provides funding for innovative and high-risk technology development projects in biomedical research that are in the early exploratory stages and have not yet been proven feasible.

The U.S. Department of Energys (DOE) Office of Energy Efficiency and Renewable Energy (EERE) Building Technologies Office (BTO) is issuing this Funding Opportunity Announcement (FOA) titled Bipartisan Infrastructure Law (BIL): Resilient and Efficient Codes Implementation (RECI). The current FOA represents the second installment in the RECI initiative, which maintains the same broad format, flexibility, and crosscutting areas of interest, while emphasizing and prioritizing specific gaps, needs, and opportunities to support building energy codes identified as focal points through the first RECI FOA and continued stakeholder engagement. The activities to be funded under the FOA support the BIL, as well as a broader government-wide approach to advance building codes and support their successful implementation. The primary focus centers around updating to more efficient building energy codes that save money for American homes and businesses, reduce greenhouse gas (GHG) emissions, and encourage more resilient buildings. This FOA includes one topic area broadly focused on the cost-effective implementation of updated energy codes.

This grant provides funding for innovative and high-risk research projects in biomedical, behavioral, or clinical fields, aimed at early-stage ideas that could lead to significant advancements.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

The BLM Arizona Cultural Heritage Partnership Program (CHPP) supports projects advancing the Department of Interior's priorities, including addressing the climate crisis, restoring balance on public lands, advancing environmental justice, and investing in a clean energy future. Projects should focus on public archaeology education, the development of educational programs, repatriation of Native American remains, and cultural resource inventory. Eligible applicants include higher education institutions, non-profits, state and local governments, and Indian tribal governments. The program aims to support projects that use science, data, and traditional knowledge to enhance economic opportunities for communities of color, low-income families, and rural and indigenous communities.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research community. A goal of this Centers program is to support important and innovative research in the muscular dystrophies that is best pursued through an interdisciplinary and collaborative center environment and projects that may not be as effective if supported by "stand-alone" research project grants. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Finally, Center investigators are expected to engage the patient and advocacy communities in conversations to increase awareness of research, encourage patient participation in research, and incorporate the perspectives of these communities in the conduct of patient-centered research.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.